Supplementary material from Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stéphanie Lheureux(Princess Margaret Cancer Centre), Amit M. Oza(Ontario Institute for Cancer Research), C. Blake Gilks(Vancouver General Hospital), Zhongwu Lai(AstraZeneca (United States)), Stan B. Kaye(Institute of Cancer Research), Julia V. Burnier(McGill University), David D.L. Bowtell(The University of Melbourne), Sarah Runswick(Allgemeine Gewerbeschule Basel), Katherine Karakasis(Princess Margaret Cancer Centre), Kirsten M. Timms(Myriad (Germany)), J. Carl Barrett(National Institute of Environmental Health Sciences), Elise C. Kohn(National Cancer Institute), Ursula A. Matulonis(Dana-Farber Cancer Institute), Mark J. O’Connor(AstraZeneca (United Kingdom)), Jerry S. Lanchbury(Myriad Genetics), Tony Panzarella(Princess Margaret Cancer Centre), Jonathan A. Ledermann(London Cancer), Brian Dougherty(AstraZeneca (United States)), Darren Hodgson(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Tony W. Ho(Johns Hopkins University), Charlie Gourley(Edinburgh Cancer Research)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k